China Diabetes Drugs And Devices Market Size (2024 - 2029)

The market size for diabetes drugs and devices in China is projected to experience growth over the forecast period, driven by various factors including the high prevalence of diabetes, particularly among COVID-19 patients, and the increased demand for insulin. The complexity of insulin production and the competitive landscape among manufacturers further influence the market dynamics. Additionally, the challenges faced by individuals with diabetes during the quarantine, such as medication shortages, highlight the critical need for effective diabetes management solutions. These elements collectively contribute to the anticipated expansion of the market.

Market Size of China Diabetes Drugs And Devices Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
China Diabetes Drugs And Devices Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 19.66 Billion
Market Size (2029) USD 22.77 Billion
CAGR (2024 - 2029) > 3.50 %

Major Players

China Diabetes Drugs And Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

China Diabetes Drugs And Devices Market Analysis

The China Diabetes Drugs And Devices Market size is estimated at USD 19.66 billion in 2024, and is expected to reach USD 22.77 billion by 2029, growing at a CAGR of greater than 3.5% during the forecast period (2024-2029).

Diabetes affects about one out of every ten COVID-19 patients in China. Diabetes is linked to an increased risk of serious disease and death. The current study suggests that COVID-19 individuals with diabetes require focused early intervention. According to Peking University (Beijing, China), research, intensive care unit (ICU) patients had an approximately threefold higher prevalence of diabetes than non-ICU patients. Various studies on the prevalence of diabetes have diverse results.

During the quarantine period, about 60% of persons with diabetes encountered food or medicine shortages, much greater than those without diabetes. Various studies on the prevalence of diabetes have diverse results. During the quarantine period, about 60% of persons with diabetes encountered food or medicine shortages, which was much more significant than those without diabetes. Notably, respondents who reported medication shortages had a 63% higher rate of COVID-19 infection.

Type 1 diabetes patients will account for more than 9.5% of China's overall diabetes population in the current year. Blood glucose swings among insulin users are common in China owing to lifestyle and eating habits, and self-monitoring of blood glucose fails to adequately reflect the blood glucose profile since it only shows the glucose concentration at a single time point.

China has the highest number of diagnosed and undiagnosed diabetes cases in the world, as per Diabetes Research and Clinical Practice. The number of diagnosed diabetics in China has increased by 56% from 2011 to 2021. Over 75% of adults with diabetes reside in low- and middle-income countries. Diabetes-related health expenditures have surged by 316% to USD 966 billion globally over the past 15 years, with China ranking second with USD 165.3 billion.

Thus, a trend in the demand for diabetes drugs in China has been noted. In the pharmaceutical sector, insulin has a substantial market share. Insulin is used by around 100 million individuals worldwide, including all Type 1 diabetes patients and 10% to 25% of Type 2 diabetic patients. Insulin production is exceedingly complex, with just a few insulin manufacturers on the market. As a result, there is tremendous competition among these companies, which always seek to meet patient requests by offering the highest-quality insulin.

Thus, the above factors are expected to drive market growth over the forecast period.

China Diabetes Drugs And Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be injected several times daily, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections such as insulin. The Chinese diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring). The report offers value (in USD) and volume (in units) for the above segments.

Devices
Monitoring Devices
Self-monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices
Insulin Pump
Insulin Syringes
Insulin Cartridges
Disposable Pens
Drugs
Oral Anti-Diabetes Drugs
Insulin Drugs
Combination Drugs
Non-Insulin Injectable Drugs
Need A Different Region Or Segment?
Customize Now

China Diabetes Drugs And Devices Market Size Summary

The China diabetes drugs and devices market is poised for significant growth over the forecast period, driven by the increasing prevalence of diabetes and the rising demand for effective management solutions. As the country grapples with the highest number of diagnosed and undiagnosed diabetes cases globally, the market is witnessing a surge in both pharmaceutical and device sectors. Insulin remains a cornerstone of diabetes treatment, with its complex production fostering intense competition among manufacturers to meet the needs of a vast patient population. The market is also experiencing advancements in continuous blood glucose monitoring technologies, which are becoming more accessible and affordable, thereby enhancing patient care and treatment outcomes.

China's healthcare system is actively responding to the diabetes epidemic through strategic initiatives and policy reforms aimed at improving disease management and control. The integration of academic medical centers and primary care providers is a key focus, promoting health education and self-management among patients. The competitive landscape of the diabetes market is characterized by mergers, acquisitions, and partnerships among major players, who are continually innovating to maintain their market positions. Recent policy changes, such as the centralized procurement of insulin, have further reduced costs, making high-quality diabetes care more accessible. These factors collectively contribute to the anticipated growth of the diabetes drugs and devices market in China.

Explore More

China Diabetes Drugs And Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Dynamics

      1. 1.2.1 Market Drivers

      2. 1.2.2 Market Restraints

    3. 1.3 Porter's Five Forces Analysis

      1. 1.3.1 Bargaining Power of Suppliers

      2. 1.3.2 Bargaining Power of Consumers

      3. 1.3.3 Threat of New Entrants

      4. 1.3.4 Threat of Substitute Products and Services

      5. 1.3.5 Intensity of Competitive Rivalry

  2. 2. Market Segmentation (Market Size by Value - USD)

    1. 2.1 Devices

      1. 2.1.1 Monitoring Devices

        1. 2.1.1.1 Self-monitoring Blood Glucose Devices

        2. 2.1.1.2 Continuous Blood Glucose Monitoring

      2. 2.1.2 Management Devices

        1. 2.1.2.1 Insulin Pump

        2. 2.1.2.2 Insulin Syringes

        3. 2.1.2.3 Insulin Cartridges

        4. 2.1.2.4 Disposable Pens

    2. 2.2 Drugs

      1. 2.2.1 Oral Anti-Diabetes Drugs

      2. 2.2.2 Insulin Drugs

      3. 2.2.3 Combination Drugs

      4. 2.2.4 Non-Insulin Injectable Drugs

China Diabetes Drugs And Devices Market Size FAQs

The China Diabetes Drugs And Devices Market size is expected to reach USD 19.66 billion in 2024 and grow at a CAGR of greater than 3.5% to reach USD 22.77 billion by 2029.

In 2024, the China Diabetes Drugs And Devices Market size is expected to reach USD 19.66 billion.

China Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)